<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13264">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01882907</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237AKR05T</org_study_id>
    <nct_id>NCT01882907</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes</brief_title>
  <official_title>An Open-label, Randomized, Active-controlled Study to Compare the Effect of 16 Weeks Treatment With Vildagliptin to Pioglitazone as add-on Therapy to Metformin in Type 2 Diabetic Patients Inadequately Controlled With Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin
      to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes
      inadequately controlled with metformin monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by
      hyperglycemia that result from  pancreatic islet dysfunction. Presently available oral
      antihypoglycemic drug improves glycemic control over the short term, none has been shown to
      stop the progressive decline in beta cell function which contributes to the deterioration of
      glycemic control over time.

      Pathophysiology of T2DM is known as tissue resistance for insulin and progressive beta cell
      failure. Which one attributes first is unclear, but non-obese T2DM patients often show
      normal fasting plasma glucose (FPG) but postprandial plasma glucose (PPG) level is high and
      reduced or lacking normal compensatory insulin secretion. In Korea, more than 80% of T2DM
      are non-obese type (BMI &gt;= 27 ) and it was observed that basal insulin level and
      compensatory insulin secretion reaction were reduced in normal healthy population. Based on
      that, metformin is an established first line treatment for type 2 diabetes, acting primarily
      to enhance hepatic and peripheral insulin sensitivity. However, it has become increasingly
      apparent that many patients require a combination of agents to attain optimal glycemic
      control.

      Better understanding of incretin effect on the pathophysiology of T2DM has recently led to
      development of new oral hypoglycemic agents. Vildagliptin is a potent and highly selective
      dipeptidyl peptidase (DPP)-IV inhibitor that improves islet function by increasing
      pancreatic alpha and beta cell responsiveness to glucose. Studies in patients with T2DM have
      shown that vildagliptin significantly reduced HbA1c and FPG level from baseline and did not
      induce weight gain and the incidence of hypoglycemia was low. In addition, studies in
      rodents support an effort of vildagliptin on beta cell remodeling.

      The thiazolidinediones are effective in reducing HbA1C in obese T2DM patients and it is
      known that only thiazolidinedione can delay the beta cell failure . But recently,
      thiazolidinediones were found to be associated with a decrease in bone mineral density and
      to raise the risk of myocardial infarct and cardiovascular related mortality. Thus, there is
      a need for new classes of blood glucose lowering drug which has the potential to delay or
      prevent the progression of T2DM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Non-inferiority of HbA1C change from baseline in vildagliptin + metformin group compared with pioglitazone + metformin group</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare changes of FPG and PPG from baseline between vildagliptin + metformin and pioglitazone + metformin groups</measure>
    <time_frame>16 weeks , visit 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare changes of lipid profiles from baseline between vildagliptin + metformin and pioglitazone + metformin groups</measure>
    <time_frame>16 weeks, visit 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare changes of body weight from baseline between vildagliptin + metformin and pioglitazone + metformin groups</measure>
    <time_frame>16 weeks, visit 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare numbers of participants with adverse events between vildagliptin + metformin and pioglitazone + metformin groups</measure>
    <time_frame>16 weeks, visit 3,4,5</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety assessments
- hypoglycemia, other side effects, Laboratory data, Physical examination, Vital sign with blood pressure and pulse rate, Electrocardiography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To compare changes of insulin and C-peptide from baseline between vildagliptin + metformin and pioglitazone + metformin groups</measure>
    <time_frame>16 weeks, visit 5</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>To compare changes of Homeostasis model assessment-insulin resistance and beta from baseline between vildagliptin + metformin and pioglitazone + metformin groups</measure>
    <time_frame>16 weeks, visit 5</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>To compare changes of adipocytokine from baseline between vildagliptin + metformin and pioglitazone + metformin groups</measure>
    <time_frame>16 weeks, visit 5</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">293</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vildagliptin add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <description>vildagliptin 50mg bid for 16 weeks</description>
    <arm_group_label>vildagliptin</arm_group_label>
    <other_name>Galvus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 15mg bid for 16 weeks</description>
    <arm_group_label>pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age in the range of 18 to 80 years

          2. HbA1c 7 to 11%

          3. FPG &lt; 270 mg/dL (15 mmol/L);

          4. Agreement to maintain prior diet &amp; exercise

          5. Written informed consent to participate in the study

        Exclusion criteria:

          1. Type 1 diabetes or Any kind of secondary diabetes

          2. Pregnant or lactating women

          3. Acute infections which may affect blood glucose control within 4 weeks prior to visit
             1.

          4. Significant diabetes complications e.g., symptomatic autonomic neuropathy or
             gastroparesis

          5. Previous history of severe cardiovascular disease such as

               1. Torsades de Pointes, sustained and clinically relevant ventricular tachycardia,
                  or ventricular fibrillation

               2. Percutaneous coronary intervention within the past 3 months

          6. Any of the following within the past 6 months

               1. Myocardial infarction (MI) (if the visit 1 ECG reveals patterns consistent with
                  an MI and the date of the event cannot be determined, then the patient can enter
                  the study at the discretion of the investigator and the sponsor)

               2. Coronary artery bypass surgery

               3. Unstable angina

               4. Stroke

          7. Congestive heart failure (NYHA class I to IV)

          8. Liver disease such as cirrhosis or chronic active hepatitis

          9. Known sensitivity to pioglitazone, rosiglitazone, or similar drugs

         10. Chronic insulin treatment (&gt; 4 weeks of treatment in the absence of an intercurrent
             illness) within the past 6 months

         11. Chronic oral or parenteral corticosteroid treatment (&gt; 7 consecutive days of
             treatment) within 8 weeks prior to visit 1

         12. Any of the following laboratory abnormalities

               1. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) greater than
                  2.5 times the upper limit of the normal range at visit 1

               2. Direct bilirubin greater than 1.3 times the upper limit of the normal range at
                  visit 1

               3. Serum creatinine levels &gt; 2.5 mg/dL (220 Î¼mol/L) at visit 1

               4. Clinically significant thyroid-stimulating hormone (TSH) outside normal range at
                  visit 1
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Ju Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Baik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-AUniversity Medical Center</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Busan Saint Mary's Medical Center</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changwon Fatima Hospital</name>
      <address>
        <city>Changwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungbuk National Universtiy Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chosun University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masan Samsung Medical Center</name>
      <address>
        <city>Masan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>June 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vildagliptin</keyword>
  <keyword>metformin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
